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Table
Median Cell Dose/kg Pre and Post TCD
Cells TNC CD34 CD3 CD4 CD8 TCR gd CD56/16
Pre BM 3.81E+08 5.87E+06 2.69E+07 1.32E+07 1.27E+07 1.26E+06 3.86E+06
Pre PBSC 1.19E+09 8.72E+06 2.38E+08 1.37E+08 2.59E+08 9.71E+06 3.59E+07
SBA-E- 2.84E+07 1.86E+06 6.07E+04 8.30E+03 4.04E+04 1.20E+04 6.73E+05
Iso E- 7.63E+06 7.31E+06 1.58E+03 3.88E+02 7.78E+02 <1.00E+02 2.25E+03
Clini 8.53E+06 1.05E+07 3.56E+03 2.06E+03 1.49E+03 <1.00E+02 6.98E+02
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The table shows post TCD T cell doses were signiﬁcantly
higher in BM than in PBSC grafts. In TCD BM, the median log
10 depletion of CD3 + T cells (2.65) was signiﬁcantly different
from IsoE log10 TCD (5.22). Clini log 10 TCD (4.92) was
similar to IsoE. Strikingly, while preprocessed BM had fewer
NK CD56/16+ than PBSC (3.86E+06 vs. 3.59E+07), the nega-
tive selection of BM left more NK cells in the TCD graft,
resulting in signiﬁcantly higher NK cell dose (6.73E+05) than
after CD34+ positive selection by Iso E- (2.25E+03) or Clini
(6.98E+02). IsoE- had signiﬁcantly (P < .001) higher CD34
doses (7.31E+06 /kg) and greater recovery (85.0%) of CD34+
cells; than SBA-E- (1.86E+06 /kg, 33.3% recovery). Clini
selection resulted in similar CD34 cell doses and recovery to
the IsoE-. (1.05E+07/kg, 116.74 % recovery). Number and
types of CD3+ T cells, T subpopulations, NK, and CD34+ in
TCD grafts act in concert with donor and host parameters to
effect ﬁnal transplant outcome. Characterization of cells in
preprocessed grafts and retained by TCDmethods can lead to
better graft engineering and optimization of the cellular
content of the ﬁnal T depleted product.413
Cord Blood Storage for ‡ 5 Years Does Not Impact
Engraftment
Simrit Parmar 1, Marcos de Lima 1, Elizabeth J. Shpall 1,
Gabriela Rondon 2. 1 UT MD Anderson Cancer Center, Houston,
TX; 2 Stem Cell Transplantation and Cellular Therapy, The
University of Texas MD Anderson Cancer Center, Houston, TX
The impact of the years of storage of an umbilical cord blood
unit (CBU) on its engraftment potency is not known. We
analyzed engraftment kinetics of 15 Old CBUs deﬁned as
stored for more than 5 years and compared it to 71 Younger
CBUs for end points of time to neutrophil and platelet
engraftment. The median duration of storage for the Old
CBUs was 5.6 years (5.6-12.2 years). For Old vs. Young CBUs,
the average total nucleated count was 0.5 x106 vs. 55x106 (P
¼ .004), cryopreservation volume of 72ml vs. 70ml (P ¼ .9),
CD34 count of 0.19x106/kg vs. 0.23x106/kg (P ¼ .7). There
were no differences in the processing of the CBUs. The donor
characteristics for the Old vs. Young CBUs were Caucasian
race: 7% vs. 24% (P < .0001)and female sex: 43% vs. 49% (P ¼
.3). The recipient characteristics for the Old vs. Young CBUs
were: female sex: 57% vs. 45% (P ¼ .4), Caucasian race 43% vs.
63% (P < .0001), recipient weight 30kg vs. 38kg (p¼NS),
recipient age 14 vs. 16 years (p¼NS). The transplant condi-
tioning, GVHD prophylaxis and degree of HLA mismatch was
comparable for the two groups. There were no differences in
the engraftment kinetics for the Old vs. Young CBUs with
time to neutrophil engraftment of 21 vs. 22 days (P ¼ .5);
platelet engraftment of 43 vs. 42 days (P ¼ .3). Early deaths
were comparable 7% vs. 6%, no differences were noted in the
duration of hospitalization. We conclude that Old CBUs
should remain as a potential source of stem cells.414
IL-15 Alone Supports in Vitro Generation of Polyclonal
CTL From CD3/CD28 Co-Stimulated Expanded CB T Cells
Against Leukemia Cells
Jeyaraj Antony 1, Xiaohua Chen 2, Paul Szabolcs 3. 1 Pediatrics,
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA;
2 pediatrics, Children's Hospital of Pittsburgh of UPMC,
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Background: Ex vivo expanded CBTcells (with CD3/CD28 co-
stimulatory beads + IL-2 and IL-7) are receptive to subse-
quent in vitro priming against killed lymphoid and myeloid
leukemia cells in the presence of IL-7, IL-12, and IL-15. This
had been reported from our lab (Davis et al. Cancer Research
2010, 70(13): 5249).
Objectives:We tested 1) the minimum cytokine and priming
requirements, hypothesizing that higher speciﬁcity may be
obtained if fewer exogenous cytokine is employed. 2)
Determine the critical recognition element of cytotoxicity. 3)
Characterize the cellular phenotype associated with the CTL
activity.
Methods: CTL was generated from already expanded (<3% of
a typical cord blood graft) >98% pure T cells either with
a combination of cytokines IL-7, -12 & -15 (n¼4) versus IL-15
(n¼5), versus IL-7 (n¼3) alone. After 2nd and 3rd weeks of
CTL cultures, the cytotoxicity was tested against fresh IM9
leukemia cells using europium ligand (EuTDA) release assay.
The blocking with HLA class I & II and TCRgd antibodies were
done before performing the CTL assay (n¼3). ELISPOT assay
was done to test the speciﬁcity as measured by IFN-g spot
forming cells (SFC). Eight colors FACS analysis was done
using FACS canto II, to analyze the CTL's phenotype.
Results: After 3 weeks of priming, the mean speciﬁc lysis of
CTL generated using IL-15 alone versus combination of
cytokines on fresh IM9 cells was 79% and 80% respectively at
an E/T ratio of 40:1 (Figure-1). CTL generated using IL-15
alone has a speciﬁc lysis of 90% at the end of second priming
(n¼4). The CTL's exhibit no cytotoxicity against non-speciﬁc
targets (myeloid leukemia cell line U937). The expanded CBT
cells primed with IL-15 alone, but without being exposed to
IM9 cells did not acquire speciﬁc cytotoxicity (n¼4). While
cytotoxicity was comparable, CTL from IL-15 alone cultures
displayed higher speciﬁcity in ELISPOTassays with much less
non-speciﬁc target recognition as measured by IFN-g spot
forming cells (SFC) (n¼2).
Eventhough, no single blockingMoAb completely abolished
cytotoxicity, the most signiﬁcant diminution was identiﬁed
when the effectors were blocked with TCRgd. Multicolor
FACS analysis indicates that after exposing the CTLs to
speciﬁc targets, w6-7% of the cells are secreting IFN-g in
response and 6-20% are TCRgd positive. Immunoscope
analysis of TCRgd spectratype identiﬁes oligoclonal restric-
tion of CTL cultures with lytic activity compared to identical
cytokine expanded T cells lacking leukemiaespeciﬁc CTL
activity.
Figure 1. Cytotoxic activity (mean and standard deviation) of lymphoid
leukemia-speciﬁc cord blood T cells expanded in cytokine cocktails IL-7, -12, &
- 15(n¼4) or IL-15 (n¼5) and IL-7 alone (n¼3)
Table 1
Dispose Reason N % of disposed
CBU/barcodes
(n¼77149)
Low TNCC 30815 39.9
Low Volume 17415 22.6
Placenta issue 7279 9.4
Not collected 5356 6.9
Maternal history problem 3817 4.9
Cord issue 3693 4.8
Low Viability 1404 1.8
Processing issues 1159 1.5
Cord clot 872 1.1
Maternal Sample Problem 750 1.0
Consent refused/withdrawn 567 0.7
Donate/research 553 0.7
Data Missing 546 0.7
Failed CBU Sterility 529 0.7
Subsequent Med Info 476 0.6
CBU Expired 364 0.5
Delivery complication 326 0.4
Training unit 307 0.4
Collection kit issue 301 0.4
Cryopreservation 251 0.3
Abnormality in baby 232 0.3
Potency/CFU 88 0.1
NRBC >50% 49 0.1
TOTAL 77149
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ated with IL-15 alone from previously CD3/CD28 expanded
CB T cells. While the cytotoxicity is comparable to those
primed/expanded by combinations of cytokines, the CTL
speciﬁcity is higher with IL-15 alone. Notably, the CTL activity
is not conﬁned to a single cellular subset and resides in the
TCRgd+ T cell.415
Why Do Umbilical Cord Blood Units Fail to Qualify for
Public Banking?
Jessica Wishnew 1, Stephen Wease 2, Jose Hernandez 3,
Kristin Page 1, Joanne Kurtzberg 1. 1 Pediatric Blood and
Marrow Transplant Program, Duke University Medical Center,
Durham, NC; 2 EMMES Corporation, Rockville, MD; 3 Carolinas
Cord Blood Bank, Duke University, Durham, NC
Background: The goal of the Carolinas Cord Blood Bank
(CCBB), a public cord blood (CB) bank, is to procure quality
cord blood units (CBU) for use in hematopoietic stem cell
transplantation. The banking process is comprised of donor
screening, collection, processing, cryopreservation and
testing. At each step, CBU eligibility is determined and units
not meeting speciﬁcations are discarded. We explored
reasons for CBU disposal to identify strategies to maximize
the number of successfully banked CBUs.
Study design and methods: The CCBB database was retro-
spectively analyzed to characterize and quantify reasons
CBUs were ineligible for banking. The reasons for discard
were collated, assigned to a step on a process chain and
assigned to a category. Speciﬁcations for banking included
a minimum volume of 40ml (to 2005) and 60ml (to present),
a preprocessing total nucleated cell count (TNCC) of
1x109cells and a post processing viability of >90%.
Results: From 1/1998-8/2012, 109,177 total CBU donors
registered in the database. Of these, 34% did not have CBUs
collected because of unavailable collection staff, placental/
cord damage or CB clot, among other reasons. A total of
71,618 CBUs were collected, 40,986 (57%) of which were
shipped to the processing lab. Twenty-two percent of the
CBUs sent for processing were subsequently discarded. Time
points for discard of collected CBUs were: 43% before pro-
cessing, 5% during processing and 7% after cryopreservation.
Reasons for disposal of 77,149 registrations or CBUs (Table 1)
included 40% for low TNCC, 23% for low volume, 2% for low
viability, and 0.7% for failed sterility.
Conclusion: We identiﬁed reasons for banking failures in
a large public CB bank. While small volumes/low TNCC rep-
resented the major reasons for failure of collected CBUs to bebanked, other factors inﬂuenced the failure to collect CBUs
from recruited volunteer donors. Improving MD and tech-
nician training to increase the volume of collections and
awareness of collection procedures in regards to placenta
and cord handling, as well as expanding program collection
hours, could impact the overall banking success. The ﬁnan-
cial impact of CBU losses will also be discussed.
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The Use of Early Spirometric Changes and IGF-1 Levels for
the Detection of Patients at Risk for BOS
Sameem Abedin 1, Gregory Yanik 2, John Magenau 3,
Attaphol Pawarode 3, Steven C. Goldstein 3, Carrie L. Kitko 2,
Eric White 4, Daniel R. Couriel 3. 1 Internal Medicine, University
of Michigan Health System, Ann Arbor, MI; 2 Blood and Marrow
Transplant Program, University of Michigan, Ann Arbor, MI;
3 Adult Blood and Marrow Transplant Program, University of
Michigan; 4 Pulmonary and Critical Care, University of
Michigan, Ann Arbor, MI
Introduction: Bronchiolitis Obliterans Syndrome (BOS) is
the manifestation of chronic GVHD (cGVHD) of the lung, it
affects approximately 10% of patients surviving one year post
transplantation (2), and the survival at 5 years is only about
10% (3). A timely diagnosis could improve the outcome of
this potentially fatal disease.
Methods: Using a lung transplantation scoring system (4),
we retrospectively evaluated 23 consecutive BOS patients to
determine whether an FEV1<90% and FEF25-75<75% (stage
BOS 0p), would have contributed to earlier detection. Addi-
tionally, we assessed IGF-1 (insulin growth factor 1) levels,
a proﬁbrogenic mediator (1), in serum samples of patients at
onset of cGVHD (n¼57), including 13/23 patients with
a diagnosis of BOS. A retrospective chart review was per-
formed to identify patients meeting the NIH Consensus
clinical deﬁnition of chronic GVHD of the lung (BOS) between
2007 and 2011. The criteria included: 1) FEV1 < .8 2) FEV1/
FVC < .75 and RV> 120% and 3)no evidence of infection on
most recent imaging or BAL at time of diagnosis. The dates
